Global Forecasting & Insights Director

CSPC Pharmaceutical & AstraZeneca form joint venture for biologics manufacturing in China. CSPC Pharmaceutical and AstraZeneca have formed a 51:49 joint venture to build a biologics manufacturing facility in Shijiazhuang. CSPC Pharmaceutical Group and AstraZeneca have entered into a joint venture contract to build a new-generation biologics manufacturing facility in Shijiazhuang, China. The venture marks the third strategic agreement the two companies have struck in as many years, and is expected to focus on the manufacturing and supply of mutually agreed biologics drug substances for global markets, with the companies contributing capital at a 51:49 equity ratio in favor of CSPC.[1] What are the terms of the joint venture? Under the terms of the joint venture contract, CSPC and AstraZeneca will jointly manage construction along with day-to-day operations, drawing on their respective strengths. As the business develops, production capacity scales up, and commercial demand grows, the companies say they will explore incorporating additional products into the joint venture's scope.[1] The agreement remains subject to customary closing conditions, including regulatory approvals. The joint venture is designed to combine CSPC's AI-driven Good Manufacturing Practice system and its pharmaceutical manufacturing construction and operational capabilities with AstraZeneca's expertise in global quality standards and supply chain management.[1] The initial business scope centers on biologics drug substances, with both companies committing to delivering high-quality medicines to patients worldwide. Why does this matter for CSPC's global ambitions? CSPC says the collaboration reflects strong recognition of its modernized manufacturing system, quality management capabilities, and industrial-scale execution by a leading global multinational pharmaceutical company. The company frames the joint venture as extending its internationalization path from "going global with products and technologies" to "going global with manufacturing systems and supply chain capabilities."[1] As global pharmaceutical companies continue to optimize research, manufacturing, and supply chain footprints, CSPC argues that high-quality, efficient, and sustainable manufacturing and supply capabilities are becoming a core competency across the global innovative drug value chain, laying groundwork for more of its innovative drug products to enter international markets. Previous deals between CSPC and AstraZeneca. The manufacturing joint venture builds on a fast-deepening relationship between the two companies. In June 2025, AstraZeneca and CSPC entered a to discover and develop pre-clinical oral candidates against high-priority targets across multiple chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases.[2] The research is being carried out by CSPC in Shijiazhuang using its AI-driven, dual-engine drug discovery platform. As part of the agreement, CSPC received an upfront payment of $110 million and eligiblity for up to $1.62 billion in development milestone payments and upwards of $3.6 billion in sales milestone payments.[2] More recently, the companies struck a for obesity and type 2 diabetes across eight programs, four of which will progress initially using CSPC's AI-driven peptide drug discovery platform and its proprietary LiquidGel once-monthly dosing technology.[3] AstraZeneca secured exclusive global rights outside China to CSPC's once-monthly injectable weight management portfolio, including SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, and three preclinical programs.[3] What comes next? With the biologics manufacturing joint venture still pending regulatory clearance, CSPC says it believes the new facility will strengthen its ability to meet international manufacturing and supply demand while supporting the broader pipeline of products emerging from its expanding partnership with AstraZeneca.

Are your kidneys OK+ official launch | together with AstraZeneca. AreYourKidneysOK+? Officially Launched to Advance Early Detection in Cardio-Kidney-Metabolic Care | While diabetes, chronic kidney disease (CKD), and cardiovascular disease are widely recognised, fewer people are aware of hyperkalemia (high potassium levels), a serious condition that can occur alongside these diseases and increase the risk of life-threatening complications. That's why raising awareness and encouraging early screening are essential to helping more Malaysians understand their risks and seek timely care. Today, together with AstraZeneca, Alpro Pharmacy is proud to launch AreYourKidneysOK+?, a kidney health awareness initiative dedicated to advancing early detection and improving awareness of cardio-kidney-metabolic (CKM) health. | Through this initiative, 12,550 subsidised blood test screenings will be made available to support earlier risk detection through key health markers, including blood sugar, cholesterol, kidney function, and potassium levels. The programme is further complemented by a dedicated online hyperkalemia education platform and teleconsultation services, making trusted health information, professional guidance, and follow-up care more accessible than ever. The launch also featured an expert panel discussion, "Diabetes Risk to Kidney Protection: Supporting Earlier Recognition of Hyperkalemia Risk," where a nephrologist, an endocrinologist, and a pharmacist shared insights on multidisciplinary care, patient empowerment, and the importance of early intervention. Attendees also explored a series of interactive hyperkalemia educational stations by AstraZeneca, offering engaging learning experiences that reinforced the importance of kidney health and early detection. Because every screening is more than just a test, it is an opportunity to detect risks earlier, take action sooner, and protect your kidneys, your heart, and your future. | | Learn more: https://edu.alpropharmacy.com/a/?a=NzY= #AlproPharmacy #AreYourKidneysOK+ #KidneyHealth #CKDAwareness #Hyperkalemia #CardioKidneyMetabolic #PreventiveHealthcare #EarlyDetection #AstraZeneca

AstraZeneca and Bristol Myers Squibb have held initial discussions about a potential merger that would create a combined entity worth nearly $400 billion, according to reports citing people familiar with the matter. The market reaction was sharply negative, with AstraZeneca shares falling more than 8%, wiping out roughly $22 billion in market value, whilst Bristol Myers dropped almost 1.5%. The deal would strengthen AstraZeneca's cancer and cardiovascular drug portfolios, which accounted for 44% and 22% respectively of its $59 billion revenue last year. Bristol Myers faces upcoming patent losses for key drugs including immunotherapy Opdivo and blood thinner Eliquis. Analysts questioned the strategic rationale, noting AstraZeneca's recent success under CEO Pascal Soriot.